However, ATP1B1 shows only a trend toward lower expression in CN-AML patients with NPM1 mutation, as well as a slight trend toward higher expression in patients with single or double CEBPA mutation, which is not consistent with the known prognostic role of CEBPA mutations. Here, NPM1 is linked to acute myeloid leukemia.